Adaptimmune Therapeutics PLC(ADAP)Finding the best opportunities to buy and sell stocks daily.
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It also develops ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, non-small cell lung cancer (NSCLC), esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma; ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cell; and ADP-A2M10 that is in the phase I clinical trials for the treatment of NSCLC, as well as urothelial, melanoma, and head and neck cancers. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to targets co-developing T-cell therapy. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
All stock recommendations and comments are all opinions. Investors should be cautious about any and all stock recommendations and should consider the source of any advice on stock selection. Various factors, including personal ownership, may influence or factor into a stock analysis or opinion. All investors are advised to conduct their own independent research into individual stocks before making a purchase decision. In addition, investors are advised that past stock performance is not indicative of future price action.